Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25306462 | 0.95 | RXRA (0.51) | RXRAPPARGHTR6HPGDKDM4E | |
| SCHEMBL24101807 | 0.94 | RXRA (0.50) | RXRAPPARGKDM4EALDH1A1 | |
| SCHEMBL30486779 | 0.94 | RXRA (0.50) | RXRAPPARGKDM4EALDH1A1 | |
| SCHEMBL30486784 | 0.93 | RXRA (0.49) | RXRAPPARGALDH1A1 | |
| SCHEMBL25306826 | 0.93 | RXRA (0.49) | RXRAPPARGALDH1A1 | |
| SCHEMBL25261774 | 0.92 | RXRA (0.47) | RXRAPPARGHTR6HPGDKDM4E | |
| SCHEMBL30486780 | 0.92 | RXRA (0.47) | RXRAPPARGHTR6HPGDKDM4E | |
| SCHEMBL25308654 | 0.91 | RXRA (0.47) | RXRAPPARGHPGDKDM4EALDH1A1 | |
| SCHEMBL30486778 | 0.91 | RXRA (0.47) | RXRAPPARGHPGDKDM4EALDH1A1 | |
| SCHEMBL24101806 | 0.91 | RXRA (0.61) | RXRAPPARGHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234909-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | NUCMITO PHARMACEUTICALS CO. LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234909-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | NUCMITO PHARMACEUTICALS CO. LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234909-A1 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | MMP1, IDO1, COL1A1 | RXRA 860/4885PPARG 378/4885HTR6 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.